Alice Fiévet

Alice Fiévet

Auto-generated profile, based on publicly available information

Alice Fiévet

Cancer Genetics Laboratory, Department of Medical Biology and Pathology, Gustave Roussy, 94805 Villejuif, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
Manuel RodriguesManuel Rodrigues
Manuel Rodrigues
LMLenha Mobuchon
Lenha Mobuchon
AHAlexandre Houy
Alexandre Houy
AFAlice Fiévet
Alice Fiévet
SGSophie Gardrat
Sophie Gardrat
MSMarc-Henri Stern
Marc-Henri Stern
Metastatic uveal melanoma is a deadly disease with no proven standard of care. Here we present a metastatic uveal melanoma patient with an exceptional high sensitivity to a PD-1 inhibitor associated with outlier CpG>TpG mutation burden, MBD4 germline deleterious mutation, and somatic MBD4 inactivation in the tumor. We identify additional tumors in The Cancer Genome Atlas (TCGA) cohorts with similar hypermutator profiles in patients carrying germline deleterious MBD4 mutations and somatic loss of heterozygosity. This MBD4-related hypermutator phenotype may explain unexpected responses to immune checkpoint inhibitors.

1 January 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
ABAurélie Berland
Aurélie Berland
JRJérémie Rosain
Jérémie Rosain
SKSophie Kaltenbach
Sophie Kaltenbach
VAVincent Allain
Vincent Allain
NMNizar Mahlaoui
Nizar Mahlaoui
JVJean-Pierre de Villartay
Jean-Pierre de Villartay

28 February 2019 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
NONienke J H van Os
Nienke J H van Os
LCLuciana Chessa
Luciana Chessa
CWCorry M R Weemaes
Corry M R Weemaes
MDMarcel van Deuren
Marcel van Deuren
AFAlice Fiévet
Alice Fiévet
MWMichèl A A P Willemsen
Michèl A A P Willemsen
Background: Ataxia telangiectasia (A-T) is a neurodegenerative disorder. While patients with classic A-T generally die in their 20s, some patients with variant A-T, who have residual ataxia-telangiectasia mutated (ATM) kinase activity, have a milder phenotype. We noticed two commonly occurring ATM mutations that appeared to be associated with prolonged survival and decided to study patients carrying one of these mutations. Methods: Data were retrospectively collected from the Dutch, Italian, German and French A-T cohorts. To supplement these data, we searched the literature for patients with identical genotypes. Results: This study included 35 patients who were homozygous or compound heterozygous for the ATM c.3576G>A; p.(Ser1135_Lys1192del58) mutation and 24 patients who were compound heterozygous for the ATM c.8147T>C; p.(Val2716Ala) mutation. Compared with 51 patients with classic A-T from the Dutch cohort, patients with ATM c.3576G>A had a longer survival and were less likely to develop cancer, respiratory disease or immunodeficiency. This was also true for patients with ATM c.8147T>C, who additionally became wheelchair users later in life and had fewer telangiectasias. The oldest patient with A-T reported so far was a 78-year-old patient who was compound heterozygous for ATM c.8147T>C. ATM kinase activity was demonstrated in cells from all patients tested with the ATM c.8147T>C mutant protein and only at a low level in some patients with ATM c.3576G>A. Conclusion: Compared with classic A-T, the presence of ATM c.3576G>A results in a milder classic phenotype. Patients with ATM c.8147T>C have a variant phenotype with prolonged survival, which in exceptional cases may approach a near-normal lifespan.

3 May 2019 in Human Mutation
Verified
Journal Article
Closed access
PDF file
AFAlice Fiévet
Alice Fiévet
DBDorine Bellanger
Dorine Bellanger
GRGuillaume Rieunier
Guillaume Rieunier
CDCatherine Dubois D'ENghien
Catherine Dubois D'ENghien
JSJulia Sophie
Julia Sophie
MSMarc-Henri Stern
Marc-Henri Stern

8 July 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
HTHélène Tubeuf
Hélène Tubeuf
SCSandrine M Caputo
Sandrine M Caputo
TSTeresa Sullivan
Teresa Sullivan
JRJulie Rondeaux
Julie Rondeaux
SKSophie Krieger
Sophie Krieger
AMAlexandra Martins
Alexandra Martins
BRCA2 is a clinically actionable gene implicated in breast and ovarian cancer predisposition that has become a high priority target for improving the classification of variants of unknown significance (VUS). Among all BRCA2 VUS, those causing partial/leaky splicing defects are the most challenging to classify because the minimal level of full-length (FL) transcripts required for normal function remains to be established. Here, we explored BRCA2 exon 3 (BRCA2e3) as a model for calibrating variant-induced spliceogenicity and estimating thresholds for BRCA2 haploinsufficiency. In silico predictions, minigene splicing assays, patients' RNA analyses, a mouse embryonic stem cell (mESC) complementation assay and retrieval of patient-related information were combined to determine the minimal requirement of FL BRCA2 transcripts. Of 100 BRCA2e3 variants tested in the minigene assay, 64 were found to be spliceogenic, causing mild to severe RNA defects. Splicing defects were also confirmed in patients' RNA when available. Analysis of a neutral leaky variant (c.231T>G) showed that a reduction of approximately 60% of FL BRCA2 transcripts from a mutant allele does not cause any increase in cancer risk. Moreover, data obtained from mESCs suggest that variants causing a decline in FL BRCA2 with approximately 30% of wild-type are not pathogenic, given that mESCs are fully viable and resistant to DNA-damaging agents in those conditions. In contrast, mESCs producing lower relative amounts of FL BRCA2 exhibited either null or hypomorphic phenotypes. Overall, our findings are likely to have broader implications on the interpretation of BRCA2 variants affecting the splicing pattern of other essential exons. Significance: These findings demonstrate that BRCA2 tumor suppressor function tolerates substantial reduction in full-length transcripts, helping to determine the pathogenicity of BRCA2 leaky splicing variants, some of which may not increase cancer risk.

30 October 2013 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
DBDelphine Body-Bechou
Delphine Body-Bechou
PLPhilippe Loget
Philippe Loget
DDDominique D'Herve
Dominique D'Herve
BFBernard Le Fiblec
Bernard Le Fiblec
AGAnne-Gaelle Grebille
Anne-Gaelle Grebille
PPPoulain Patrice
Poulain Patrice